JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Akciju saraksts・Smith & Nephew PLC ADR

Smith & Nephew PLC ADR

Slēgts

36.57 0.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.42

Max

36.61

Galvenie mērījumi
By Trading Economics
Ienākumi	100M 296M
Pārdošana	4.7M 3B
P/E Sektora vidējais	32.438 37.461
Dividenžu ienesīgums	2.1
Peļņas marža	9.895
Darbinieki	17,000
EBITDA	6.5M 723M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	-1.48% downside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	2.10% 2.33%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.9B 15B
Iepriekšējā atvēršanas cena	36.46
Iepriekšējā slēgšanas cena	36.57

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

26.64 / 28.37 Atbalsts un pretestība

Smith & Nephew PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 26. okt. 23:52 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. okt. 23:52 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen -- Market Talk

2025. g. 26. okt. 23:46 UTC

Tirgus saruna

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

2025. g. 26. okt. 23:41 UTC

Tirgus saruna

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

2025. g. 26. okt. 23:34 UTC

Peļņas

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

2025. g. 26. okt. 23:32 UTC

Peļņas

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

2025. g. 26. okt. 23:30 UTC

Peļņas

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

2025. g. 26. okt. 22:29 UTC

Peļņas

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

2025. g. 26. okt. 22:29 UTC

Peļņas

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

2025. g. 26. okt. 22:29 UTC

Peļņas

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

2025. g. 26. okt. 22:29 UTC

Peļņas

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

2025. g. 26. okt. 22:16 UTC

Peļņas

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

2025. g. 26. okt. 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

2025. g. 26. okt. 19:29 UTC

Iegādes, apvienošanās, pārņemšana

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

2025. g. 26. okt. 06:39 UTC

Peļņas

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

2025. g. 26. okt. 06:39 UTC

Peļņas

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

2025. g. 26. okt. 06:39 UTC

Peļņas

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. okt. 21:24 UTC

Tirgus saruna

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025. g. 24. okt. 21:07 UTC

Peļņas

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025. g. 24. okt. 20:58 UTC

Peļņas

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025. g. 24. okt. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 24. okt. 20:40 UTC

Peļņas

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025. g. 24. okt. 20:24 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:23 UTC

Peļņas

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. g. 24. okt. 20:13 UTC

Peļņas

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. g. 24. okt. 20:07 UTC

Tirgus saruna

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025. g. 24. okt. 19:40 UTC

Tirgus saruna

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025. g. 24. okt. 19:35 UTC

Tirgus saruna

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025. g. 24. okt. 19:33 UTC

Peļņas

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Smith & Nephew PLC ADR Prognoze

Cenas mērķis

By TipRanks

-1.48% uz leju

Prognoze 12 mēnešiem

Vidējais 36.05 USD -1.48%

Augstākais 37.5 USD

Zemākais 34.65 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Smith & Nephew PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

26.64 / 28.37Atbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.